contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


alligator-bioscience-resolves-on-conversion-of-series-c-shares-into-ordinary-shares-for-delivery-to-participants-in-incentive-program

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Alligator Bioscience is a research-based biotechnology company that uses patented technology to develop biological drug candidates in inflammation and cancer. The company is active in the former part of the drug development chain. Alligator Bioscience has a global technology platform and is active in a rapidly growing segment of the pharmaceutical market - protein drugs. The company was founded in 2001 and is headquartered in Lund, Sweden.

Alligator Bioscience

The board of directors of Alligator Bioscience AB (“Alligator”) has on 3 December 2024 resolved to convert 170,681 series C shares into ordinary shares for delivery of shares to participants...

<div class="mfn-preamble"><p><strong>The board of directors of Alligator Bioscience AB (“Alligator”) has on 3 December 2024 resolved to convert 170,681 series C shares into ordinary shares for delivery of shares to participants in the long-term incentive program in the form of a performance-based share saving program that was adopted at the annual general meeting held on 1 June 2021 (“LTI 2021”).</strong></p></div><div class="mfn-body"><p>The board of directors of Alligator has, in accordance with the provisions of LTI 2021, resolved to convert 170,681<strong> </strong>series C shares for allotment of 170,681 ordinary shares to the participants in LTI 2021, where 22,650<strong> </strong>ordinary shares were allotted to the CEO of Alligator and 148,031<strong> </strong>ordinary shares were allotted to other participants. In total, 31 participants have been allotted ordinary shares in LTI 2021.</p><p>The number of outstanding shares in Alligator, after the registration of the above-mentioned conversion of series C shares into ordinary shares, still amounts to a total of 758,989,086 shares, of which 758,209,917 are ordinary shares with one vote each and 779,169<strong> </strong>are series C shares with 1/10 vote each. All series C shares are held by Alligator. The total number of votes in Alligator amounts to 758,287,833.9.</p></div><div class="mfn-footer mfn-0c892b90f815"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Søren Bregenholt, CEO<br>E-mail:&nbsp;<a rel="noopener" href="mailto:sbr@alligatorbioscience.com?subject=Alligator%20Bioscience%20to%20Present%20Additional%20data%20of%20ATOR-1017%20First-in-Human%20Study%20via%20poster%20presentation%20at%20ASCO%20Annual%20Meeting%202022">soren.bregenholt@alligatorbioscience.com</a><br>Phone: +46 (0) 46 540 82 00</p></div><div class="mfn-footer mfn-a4bddb8ecc24"><hr><p><em>The information was submitted for publication, through the agency of the contact person set out above, at 12:15 p.m. CET on December 3, 2024.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/d7ccbeb6-3369-4083-92bc-b540074058cf/alligator-bioscience-resolves-on-conversion-of-series-c-shares-into-ordinary-shares-for-delivery-to-participants-in-incentive-program.pdf" class="mfn-generated mfn-primary">Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program</a></p></div>

Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!